2017
DOI: 10.1016/j.reprotox.2017.03.007
|View full text |Cite
|
Sign up to set email alerts
|

Changes in the total effective xenoestrogen burden (TEXB) of breast cancer patients during an 18-month post-surgical follow-up

Abstract: We aimed to assess changes in the total effective xenoestrogen burden (TEXB) -a biomarker of combined effect of mixtures of xenoestrogens- in breast cancer patients at surgery (breast adipose tissue) and at different time points during an 18-month follow-up (abdominal adipose tissue), and to analyze the potential influence of socio-demographic, reproductive, tumor, and treatment characteristics on TEXB levels. TEXB-alpha (due to persistent organohalogenated chemicals) and TEXB-beta (due mainly to endogenous es… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 50 publications
0
2
0
Order By: Relevance
“…These results provide support for the role of TR antagonists in the development and/or progression of PTC. Given the promising literature associating bioactivities derived from human tissues or biospecimens with various human health conditions, using these external noninvasive samplers may present new opportunities to assess potential relationships between contaminant mixtures and human health..…”
Section: Discussionmentioning
confidence: 99%
“…These results provide support for the role of TR antagonists in the development and/or progression of PTC. Given the promising literature associating bioactivities derived from human tissues or biospecimens with various human health conditions, using these external noninvasive samplers may present new opportunities to assess potential relationships between contaminant mixtures and human health..…”
Section: Discussionmentioning
confidence: 99%
“…A perspective study was conducted by the same research group in order to evaluate the effect of breast cancer treatment (chemotherapy and/or radiotherapy) and the influence of cancer progression on the EDC biomarker (Fernández et al 2017). The authors assessed the estrogenic activity of adipose tissue in breast cancer patients at the diagnosis and during four other consecutive periods (<6, 6-12, 12-18, >18 months) and found that estrogenic activity of both types of extracts (containing xenoestrogens and containing endogenous estrogens -HPLC fractionation technique) increased during the treatment with a maximum peak reached at 6-12 months, suggesting that cancer treatment might influence the levels of the EDC biomarker.…”
Section: Edc Exposure and Adult Adverse Health Effectsmentioning
confidence: 99%